A5020230532- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cancer, Lipids, and Metabolism
- Fatty Acid Research and Health
- Menopause: Health Impacts and Treatments
- Estrogen and related hormone effects
- Lipid metabolism and disorders
- Diet and metabolism studies
- Phytoestrogen effects and research
- Liver Disease Diagnosis and Treatment
- Cardiovascular Disease and Adiposity
- Health Systems, Economic Evaluations, Quality of Life
- Eicosanoids and Hypertension Pharmacology
- Cholesterol and Lipid Metabolism
- Pharmaceutical Economics and Policy
- Peroxisome Proliferator-Activated Receptors
- Diabetes Treatment and Management
- Diet, Metabolism, and Disease
- Atherosclerosis and Cardiovascular Diseases
- Cardiovascular Health and Risk Factors
- Cardiovascular Function and Risk Factors
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Sex and Gender in Healthcare
- Pharmacology and Obesity Treatment
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
Louisville Metabolic and Atherosclerosis Research Center
2017-2025
University of Utah
2008-2024
Icahn School of Medicine at Mount Sinai
2024
University of Colorado Anschutz Medical Campus
2024
University of Colorado Denver
2024
Meridian Clinical Research
2024
Brigham and Women's Hospital
2021-2023
Harvard University
2021
MedStar Washington Hospital Center
2020
Esperion Therapeutics (United States)
2020
Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers levels, but data needed to determine its effects on
Few long-term or controlled studies of bariatric surgery have been conducted to date. We report the 12-year follow-up results an observational, prospective study Roux-en-Y gastric bypass that was in United States.A total 1156 patients with severe obesity comprised three groups: 418 who sought and underwent (surgery group), 417 but did not undergo (primarily for insurance reasons) (nonsurgery group 1), 321 seek 2). performed clinical examinations at baseline 2 years, 6 12 years ascertain...
Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density (LDL) cholesterol.We conducted randomized, double-blind, placebo-controlled trial to assess the efficacy safety profile of anacetrapib in patients with coronary heart disease or at high risk for disease. Eligible who were taking statin had an LDL level was consistent recommended guidelines assigned receive 100 mg placebo daily 18 months. The primary end...
ContextAlthough niacin increases low levels of high-density lipoprotein cholesterol (HDL-C), which frequently accompany diabetes, current guidelines do not recommend use in patients with diabetes because concerns about adverse effects on glycemic control; however, this is based limited clinical data.ObjectiveTo determine the efficacy and safety lipid-modifying dosages diabetes.Design SettingProspective, randomized placebo-controlled trial conducted 6 centers from August 1993 to December...
High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these would lower the incidence of events is uncertain. Pemafibrate, a selective peroxisome proliferator–activated receptor α modulator, reduces and improves other lipid levels.
Background Menopausal hormone therapy (MHT) reportedly increases the risk of cognitive decline in women over age 65 y. It is unknown whether similar risks exist for recently postmenopausal women, and MHT affects mood younger women. The ancillary Cognitive Affective Study (KEEPS-Cog) Kronos Early Estrogen Prevention (KEEPS) examined effects up to 4 y on cognition Methods Findings KEEPS, a randomized, double-blinded, placebo-controlled clinical trial, was conducted at nine US academic centers....
Hypertriglyceridemia (triglycerides 200-499 mg/dL) is relatively common in the United States, whereas more severe triglyceride elevations (very high triglycerides, ≥500 are far less frequently observed. Both becoming increasingly prevalent States and elsewhere, likely driven large part by growing rates of obesity diabetes mellitus. In a 2002 American Heart Association scientific statement, omega-3 fatty acids (n-3 FAs) eicosapentaenoic acid (EPA) docosahexaenoic (DHA) were recommended (at...
Whether menopausal hormone therapy (MHT) protects against cardiovascular disease (CVD) remains unclear.To assess atherosclerosis progression and CVD risk factors after MHT initiated in early menopause.Randomized, controlled trial. (ClinicalTrials.gov: NCT00154180).Nine U.S. academic centers.Healthy women aged 42 to 58 years between 6 36 months from last menses without prior events who had a coronary artery calcium (CAC) score less than 50 Agatston units not received estrogen or...
In time-to-first-event analyses, icosapent ethyl significantly reduced the risk of ischemic events, including cardiovascular death, among patients with elevated triglycerides receiving statins. These are at for not only first but also subsequent events.Pre-specified analyses determined extent to which total events.REDUCE-IT (Reduction Cardiovascular Events Icosapent Ethyl-Intervention Trial) randomized 8,179 statin-treated ≥135 and <500 mg/dl (median baseline 216 mg/dl) low-density...
REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial) reported a 25% relative risk reduction in major adverse cardiovascular events with use icosapent ethyl compared pharmaceutical grade mineral oil. The mechanisms underlying this benefit remain uncertain. We explored whether treatment allocation might affect series biomarkers pathways known to associate atherosclerosis risk.Serum levels interleukin-1β, interleukin-6, high-sensitivity C-reactive protein,...
Moderate alcohol intake is associated with lower atherosclerosis risk, presumably due to increased HDL cholesterol (HDL-C) concentrations; however, the metabolic mechanisms of this increase are poorly understood.We tested hypothesis that ethanol increases HDL-C by raising transport rates (TRs) major apolipoproteins apoA-I and -II. We measured turnover these in vivo paired studies without consumption 14 subjects. The fractional catabolic rate (FCR) TR radiolabeled -II were determined last 2...
Cultured human skin fibroblasts and arterial smooth muscle cells possess high-affinity binding sites specific for high density lipoproteins (HDL). Results from the present study demonstrate that of HDL to these is up-regulated in response cholesterol loading cells. When or were preincubated with nonlipoprotein cholesterol, cellular 125I-HDL3 was enhanced severalfold. This enhancement sustained presence but readily reversed when exposed cholesterol-free medium. The stimulatory effect...
High-density lipoprotein (HDL) cholesterol (HDL-C) levels are a strong inverse predictor of atherosclerosis risk, but the physiological determinants HDL-C poorly understood. We selected 57 human subjects (30 women and 27 men) with broad range performed turnover studies apolipoprotein (apo)A-I apoA-II, two major apolipoproteins HDL, to measure fractional catabolic rate (FCR) production or transport (TR) these proteins. also measured several other parameters known correlate test for their...
Diets that reduce atherosclerosis risk lower levels of HDL cholesterol (HDL-C), but the significance this is unclear. To better understand mechanism phenomenon we studied turnover apolipoproteins A-I and A-II in 13 subjects on two contrasting metabolic diets. Upon changing from high to low intake saturated fat mean HDL-C decreased 29% 56 +/- (SD) 40 10 mg/dl, while apo fell 23% 139 22 107 mg/dl (both P less than 0.001). Mean did not change. The fractional catabolic rate (FCR) increased 11%...
Low HDL-cholesterol (HDL-C) levels may elevate atherosclerosis risk, and often associate with hypertriglyceridemia (HTG); however, the metabolic causes of low HDL-C or without HTG are poorly understood. We studied turnover radioiodinated HDL apolipoproteins, apo A-I A-II, in 15 human subjects HDL-C, six normal plasma TG (group 1) nine high 2), compared them to 13 control 3). The fractional catabolic rate (FCR) was equally elevated groups 1 2 vs. group 3 for both (0.313 +/- 0.052 0.323 0.063...